



Submit completed applications to:
info@exciteinternational.com

Full Application Form

EXCITE International creates value by accelerating the adoption of disruptive new health technology innovations into global markets, with greater certainty, at a lower cost.

Visit [our website](#) for a detailed description of the EXCITE International initiative and the application process.

Applicants will be assigned an EXCITE International lead that will be available to provide feedback and guidance on the completion of your application. Ensure that you have completed all sections of this application form and that you have included all supporting documentation in your submission. All applicants will receive confirmation of receipt within one business day.

SECTION 1 - APPLICANT INFORMATION

Company name	Contact name (Dr., Mr., Ms.)	Position	
Mailing address	Phone	E-mail	
Number of Employees	Stage of company:	Pre-Revenue	Revenue
What was the technology's annual global sales in the last fiscal year? (FY 20__ = \$_____)			

SECTION 2 – THE TECHNOLOGY

Name of medical technology:
Describe the intended health claim(s) and proposed benefit(s) of the technology
Target patient population (gender, age, medical condition(s), etc.):
Describe the safety profile of your technology (risk class in the US, EU and Canadian markets)

<p>Is this technology licensed/authorized for use in any jurisdiction? <i>If yes, please indicate markets:</i></p>	<p>Yes</p>	<p>No</p>
<p>Is an application for regulatory or reimbursement pending in any jurisdiction? <i>If yes please list here:</i></p>	<p>Yes</p>	<p>No</p>
<p>Are there any patients, clinicians, or institutions that have used or are currently using this technology? <i>If yes, provide details here:</i></p>	<p>Yes</p>	<p>No</p>
<p>Have any payer groups been made aware of the technology? <i>If yes, list here and provide context around level of engagement.</i></p>	<p>Yes</p>	<p>No</p>



SECTION 3 – PROBLEM DEFINITION

What is the specific healthcare challenge/problem that your technology addresses?

Limit response to 500 words.

Your response should address the following:

- *Problem definition*
- *Volume, incidence and prevalence of patients affected*
- *Clinical/economic/social burden and impact of the problem on (a) the patient, (b) the institution (c) the healthcare system*



SECTION 4 - COMPETITIVE SCAN/MARKET AWARENESS

Provide a summary of existing competing solutions & technologies (including current standard of care).

Limit your response to 500 words

Your response should address the following:

- *Describe the breakthrough/disruptive potential of the technology (i.e. how is it unique or how does it provide better clinical/economic outcomes)*
- *State the competitive advantages of the technology versus existing solutions (including current standard of care). Where available, provide quantitative data for comparative effectiveness.*
- *Identify any known challenges/hurdles relating to uptake of the technology (work flow changes, level of reimbursement available, shifting clinician practise behaviour, etc.)*
- *Identify opportunities for displacement/obsolescence of existing alternative solutions*

SECTION 5 - IMPACT

Summarize how successful adoption of your technology would positively impact the patient, a healthcare delivery organization and the healthcare system as a whole.

Limit your response to 500 words

Provide quantitative evidence, where appropriate, demonstrating how successful uptake of your solution would impact the following:

- *The patient (e.g. quality of life, clinical outcome, patient preference)*
- *Cost savings/avoidance to an organization and the healthcare system*
- *Additional positive impacts to organization(s) and/or the healthcare system (e.g. sustainability, process optimization, user experience, efficient use of healthcare resources, etc.)*

SECTION 6 – EVIDENCE

Provide details on evidence relating to this technology.

Limit your response to 250 words

Provide a brief description of the following:

- *Types of studies completed or anticipated and the objectives/results of the studies (as available)*
- *Evidence of early efficacy of technology through proof of concept studies*

**Additionally, a copy of all relevant studies or study protocols (either completed, in progress or anticipated) must be submitted as supporting documentation for consideration.*

SECTION 7 – BUSINESS READINESS

Describe the company's provisional or pending patents on the technology			
Does the company have the ability to manufacture or provide the technology in sufficient quantities for an evaluation?	Yes	No	Not Sure
Does the company currently have a plan in place to secure the necessary funds for completion of an EXCITE International Evaluation? (Although cost of completing an evaluation will vary based on a variety of factors, allocation of USD \$3-4M at a minimum is recommended for a multi-national trial)	Yes	No	Not Sure
Describe your company's business model with respect to commercialization and revenue generation			

SECTION 8 – EXCITE INTERNATIONAL EVALUATION REQUIREMENTS

Identify the jurisdictions where you intend to use EXCITE International evaluation data. (please check all that apply)
Canada USA Australia
EU Countries (Please specify):
Other (Please specify):

EXCITE International evaluations comprise of a number of core services aimed at generating a globally relevant evidence dossier including multinational field evaluation, systematic review, economic evaluation and advisory from payer groups and other health system decision-makers.

Indicate which of the following other options you wish to explore:

1. Patient preference analysis	Yes	No
2. Barrier to adoption analysis	Yes	No
3. Usability and human factors analysis	Yes	No
4. End user/ health system preference analysis	Yes	No
5. Post adoption evaluation through existing international initiatives	Yes	No

SECTION 9 – OTHER INFORMATION (OPTIONAL)

Provide any other information that you feel would be relevant in assessing your submission

Limit your response to 250 words



SECTION 10 – ACKNOWLEDGEMENTS

Review and initial each section below:

<p>I confirm that this application contains all existing reports, papers, articles and other materials to support claims. Note: Applicants should present all positive and negative outcomes of early work together with this application, as later stages of the evaluation will require presentation of all existing data. Failure to disclose data, including adverse event reports and information that proves material to the overall analysis may result in EXCITE International cancelling a project.</p>	
<p>I understand that all materials accompanying this application must comply with the applicable privacy and intellectual property laws and regulations.</p>	
<p>I understand that the application materials submitted must not contain any information that identifies, or could reasonably be used to identify, individual patients.</p>	
<p>I acknowledge that any materials that accompany the application may be shared with the EXCITE International Secretariat, the EXCITE International Management Board, the applicable Research Ethics Board(s), and with members of the EXCITE International Scientific Collaboration, Payers' Advisory Committee and EXCITE International Advisory Council in support of discussions, evaluations, proposals and business transactions pertaining to the application.</p>	
<p>I understand that an intake fee of US\$15,000 will be levied at the onset of engagement with EXCITE International.</p>	
<p>I understand that the cost of each evaluation is predicated on the complexity of the technology and the investigational testing protocol, including the sample size required.</p> <p>Note: Final pricing will be determined by EXCITE International after receiving the full proposal from the methodological centre selected by the International Scientific Collaboration partners to oversee the evaluation.</p>	
<p>I understand that, if I choose to enroll in the program, I am expected to fund 100% of the evaluation costs.</p>	
<p>I understand that the applicant and its affiliates should not be publicizing their participation with EXCITE International until contract agreements have been fully executed. Exceptions will be made if the company wishes to disclose that they have been prioritized into the EXCITE International program; however, the company must follow guidelines and language set by EXCITE International and gain approval on a case-by-case basis.</p>	

SECTION 11 – SIGNATURES

By signing below, the applicant attests that he or she:

- A) Has authority to submit an application to the EXCITE International program; and
- B) Has completed and enclosed or attached the required application components

EXCITE International recognizes your need for privacy. By submitting personal information to us, you agree to our collection and use of such personal information to keep a record of the applicants to the program and contact them as we assess each application. EXCITE International will keep the personal information secure and only use or disclose it for the purposes identified or as required by law.

Applicant Signature	Date
Applicant Name	Title

-- END OF FULL APPLICATION FORM --